Named Patient Program With Rotigotine Transdermal SystemNon-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With RotigotineEffects of Neupro on Cardiovascular Observations in Patients With Restless Legs SyndromeTrial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean SubjectsAn Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's DiseaseAn Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's DiseaseBioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese SubjectsA Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs SyndromeDose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs SyndromeRotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsA Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring HemodialysisSleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's DiseaseStudy to Compare Adhesiveness of Two Different Rotigotine Patch FormulationsCaregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver SupportPlacebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor SymptomsA Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown CauseA Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproPharmacokinetic Study of LY03003 in Patients With Parkinson's DiseaseA Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
P4844
Q61936657-48A3B7B1-F940-4A0A-9631-B15119531F3AQ61957266-2A025798-2F02-477A-B156-FF7509FF439DQ61966198-C52DCADD-FA99-449C-9EB9-786D43E439D2Q61975831-6038DBCC-CD30-4962-A4AE-8007B83E6EE3Q61979968-D223B1A6-D39D-4DC4-82EE-290B9FAD6614Q61980289-8611D2C6-FBBF-4A51-879C-54D60AD018A2Q63315759-19465289-5187-4DDB-848C-5A200853D384Q63316117-67A98DA4-2B5F-4DC4-AD73-071F9FC9D75BQ63319315-276D0D82-2918-4BB8-BA05-5E10DC8C45AFQ63319605-9FCDE61E-0936-471B-BA0A-5BBBF06A7A87Q63320162-36D2E4B4-33DF-4E14-9602-9EE1028A58CFQ63320588-B01A7A58-4E83-4D6B-9FD0-852092A13994Q63335262-736EBCA2-9C29-4E28-A6CA-240EFFA4A3EFQ63338030-AC5F0A50-A996-4B40-8DA5-70705CA3DFA9Q63338061-537C79E8-05D0-403F-8D9D-EBB6E8C8CA7FQ63596427-0060802B-086B-42AC-9B4E-0FBD7FBFC8E3Q63596574-C26873A6-6A10-40D5-92F0-69372345A701Q63600039-83ADC055-8F01-4885-B082-39AC539A76E0Q94234659-405F8169-C8A3-4FF8-9B51-2D4E295A2D5F
P4844
description
Agonista no ergolínico de la dopamina
@es
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
name
(6S)-Rotigotin
@de
(6S)-rotigotine
@en
Rotigotin
@sh
Rotigotin
@sr
Rotigotin
@sr-el
Rotigotina
@es
Rotigotina
@it
Rotigotine
@nl
Rotigotine
@vi
rotigotin
@nn
type
label
(6S)-Rotigotin
@de
(6S)-rotigotine
@en
Rotigotin
@sh
Rotigotin
@sr
Rotigotin
@sr-el
Rotigotina
@es
Rotigotina
@it
Rotigotine
@nl
Rotigotine
@vi
rotigotin
@nn
altLabel
(6S)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol
@en
ATC kod N04BC09
@sr
ATCvet kod QN04BC09
@sr
C19H25N1O1S1
@it
C19H25NOS
@sr
Leganto®
@en
N-0437
@en
Neupro
@de
Neupro
@sr
Neupro®
@en
prefLabel
(6S)-Rotigotin
@de
(6S)-rotigotine
@en
Rotigotin
@sh
Rotigotin
@sr
Rotigotin
@sr-el
Rotigotina
@es
Rotigotina
@it
Rotigotine
@nl
Rotigotine
@vi
rotigotin
@nn